FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093718596> ?p ?o ?g. }

• W2093718596 endingPage "801" @default.
• W2093718596 startingPage "795" @default.
• W2093718596 abstract "Poorly controlled type 2 or non-insulin dependent diabetes mellitus (NIDDM) patients exhibit high bone turnover, which decelerate with treatment according to the degree of improvement in glycemic control. In adults, higher bone turnover results in rapid bone loss. Therefore, deceleration of bone turnover is beneficial for bone. Troglitazone (Tro), a new anti-diabetic drug, is a thiazolidinedione (TZD) which promotes adipocyte differentiation by activating peroxisome proliferator activated receptor gamma (PPARgamma). Because, in the bone marrow, adipocytes and osteoblasts originate in common mesenchymal stem cells that are also essential for osteoclastogenesis, TZDs may directly affect bone metabolism. Thus, we examined the effects of Tro on metabolic bone markers in type 2 DM patients. Tro (400 mg/day) was administered to 33 type 2 DM patients for four weeks. The day before and four weeks after starting Tro, serum and urine samples were collected after overnight fasting. Metabolic bone markers and glycemic indices were assessed. As bone resorption markers, urinary free and total deoxypyridinoline as well as urinary collagen type I C-terminal telopeptide were measured; as bone formation markers, serum bone type and total alkaline phosphatase (BALP and ALP) levels along with osteocalcin (OC) were used. No significant changes in fasting plasma glucose or HbA1c levels were observed in our short-term treatment with Tro. All the bone resorption markers, BALP and ALP were significantly decreased. OC was not significantly changed. The discrepant changes of OC from all the other metabolic bone markers suggest limitation of the use of OC as a reliable bone formation marker in diabetics. Our results that Tro decreased metabolic bone markers before significantly improving glucose metabolism suggest that it has direct effects on bone and decreased bone turnover. TZDs may spare bone mass in NIDDM subjects through its dual effects on glucose and bone metabolism." @default.
• W2093718596 created "2016-06-24" @default.
• W2093718596 creator A5001659211 @default.
• W2093718596 creator A5002923621 @default.
• W2093718596 creator A5007275335 @default.
• W2093718596 creator A5038170497 @default.
• W2093718596 creator A5046784299 @default.
• W2093718596 creator A5060548271 @default.
• W2093718596 creator A5061588189 @default.
• W2093718596 creator A5062882032 @default.
• W2093718596 creator A5080266991 @default.
• W2093718596 date "1999-01-01" @default.
• W2093718596 modified "2023-10-01" @default.
• W2093718596 title "Short-Term Treatment with Troglitazone Decreases Bone Turnover in Patients with Type 2 Diabetes Mellitus." @default.
• W2093718596 cites W1639924204 @default.
• W2093718596 cites W1965953554 @default.
• W2093718596 cites W1967951907 @default.
• W2093718596 cites W1973275227 @default.
• W2093718596 cites W1975563621 @default.
• W2093718596 cites W1986392434 @default.
• W2093718596 cites W2002519246 @default.
• W2093718596 cites W2009083434 @default.
• W2093718596 cites W2015496410 @default.
• W2093718596 cites W2036891079 @default.
• W2093718596 cites W2047591801 @default.
• W2093718596 cites W2050717908 @default.
• W2093718596 cites W2055224067 @default.
• W2093718596 cites W2080988481 @default.
• W2093718596 cites W2086757825 @default.
• W2093718596 cites W2125344994 @default.
• W2093718596 cites W2128714854 @default.
• W2093718596 cites W2166752210 @default.
• W2093718596 cites W2200929372 @default.
• W2093718596 doi "https://doi.org/10.1507/endocrj.46.795" @default.
• W2093718596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10724355" @default.
• W2093718596 hasPublicationYear "1999" @default.
• W2093718596 type Work @default.
• W2093718596 sameAs 2093718596 @default.
• W2093718596 citedByCount "51" @default.
• W2093718596 countsByYear W20937185962013 @default.
• W2093718596 countsByYear W20937185962014 @default.
• W2093718596 countsByYear W20937185962015 @default.
• W2093718596 countsByYear W20937185962016 @default.
• W2093718596 countsByYear W20937185962017 @default.
• W2093718596 countsByYear W20937185962019 @default.
• W2093718596 countsByYear W20937185962021 @default.
• W2093718596 countsByYear W20937185962022 @default.
• W2093718596 crossrefType "journal-article" @default.
• W2093718596 hasAuthorship W2093718596A5001659211 @default.
• W2093718596 hasAuthorship W2093718596A5002923621 @default.
• W2093718596 hasAuthorship W2093718596A5007275335 @default.
• W2093718596 hasAuthorship W2093718596A5038170497 @default.
• W2093718596 hasAuthorship W2093718596A5046784299 @default.
• W2093718596 hasAuthorship W2093718596A5060548271 @default.
• W2093718596 hasAuthorship W2093718596A5061588189 @default.
• W2093718596 hasAuthorship W2093718596A5062882032 @default.
• W2093718596 hasAuthorship W2093718596A5080266991 @default.
• W2093718596 hasBestOaLocation W20937185961 @default.
• W2093718596 hasConcept C125870589 @default.
• W2093718596 hasConcept C126322002 @default.
• W2093718596 hasConcept C131075544 @default.
• W2093718596 hasConcept C134018914 @default.
• W2093718596 hasConcept C160160445 @default.
• W2093718596 hasConcept C170033053 @default.
• W2093718596 hasConcept C181199279 @default.
• W2093718596 hasConcept C185592680 @default.
• W2093718596 hasConcept C2776923340 @default.
• W2093718596 hasConcept C2777180221 @default.
• W2093718596 hasConcept C2778588143 @default.
• W2093718596 hasConcept C2780613262 @default.
• W2093718596 hasConcept C2780787237 @default.
• W2093718596 hasConcept C511355011 @default.
• W2093718596 hasConcept C55493867 @default.
• W2093718596 hasConcept C555293320 @default.
• W2093718596 hasConcept C673006 @default.
• W2093718596 hasConcept C71924100 @default.
• W2093718596 hasConceptScore W2093718596C125870589 @default.
• W2093718596 hasConceptScore W2093718596C126322002 @default.
• W2093718596 hasConceptScore W2093718596C131075544 @default.
• W2093718596 hasConceptScore W2093718596C134018914 @default.
• W2093718596 hasConceptScore W2093718596C160160445 @default.
• W2093718596 hasConceptScore W2093718596C170033053 @default.
• W2093718596 hasConceptScore W2093718596C181199279 @default.
• W2093718596 hasConceptScore W2093718596C185592680 @default.
• W2093718596 hasConceptScore W2093718596C2776923340 @default.
• W2093718596 hasConceptScore W2093718596C2777180221 @default.
• W2093718596 hasConceptScore W2093718596C2778588143 @default.
• W2093718596 hasConceptScore W2093718596C2780613262 @default.
• W2093718596 hasConceptScore W2093718596C2780787237 @default.
• W2093718596 hasConceptScore W2093718596C511355011 @default.
• W2093718596 hasConceptScore W2093718596C55493867 @default.
• W2093718596 hasConceptScore W2093718596C555293320 @default.
• W2093718596 hasConceptScore W2093718596C673006 @default.
• W2093718596 hasConceptScore W2093718596C71924100 @default.
• W2093718596 hasIssue "6" @default.
• W2093718596 hasLocation W20937185961 @default.
• W2093718596 hasLocation W20937185962 @default.
• W2093718596 hasOpenAccess W2093718596 @default.

• next